Metraipolis › archive › dc_85dee97000f4
Development of a high-throughput homogeneous AlphaLISA drug screening assay for the detection of SARS-CoV-2 Nucleocapsid — Europe PMC PPR:PPR203930
- Source
- Europe PMC
- Original
- https://europepmc.org/article/PPR/PPR203930
- DOI
- 10.1101/2020.08.20.258129
- License (as archived)
- CC0-1.0
- Archived
- 2026-11-07T17:31:20.808Z
- SHA-256 of the archived text
bc6fb59b6f2985094057fff2039205e564cff016b5810ee018394102825ccdd8- Stable URL of this page
https://metraipolis.com/documento/dc_85dee97000f4
How to cite
Development of a high-throughput homogeneous AlphaLISA drug screening assay for the detection of SARS-CoV-2 Nucleocapsid — Europe PMC PPR:PPR203930 — Europe PMC, https://europepmc.org/article/PPR/PPR203930 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_85dee97000f4 (Metraipolis archive dc_85dee97000f4, sha256 bc6fb59b6f2985094057fff2039205e564cff016b5810ee018394102825ccdd8)
BibTeX
@misc{dc85dee97000f4,
title = {Development of a high-throughput homogeneous AlphaLISA drug screening assay for the detection of SARS-CoV-2 Nucleocapsid — Europe PMC PPR:PPR203930},
howpublished = {Europe PMC},
url = {https://europepmc.org/article/PPR/PPR203930},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_85dee97000f4; sha256 bc6fb59b6f2985094057fff2039205e564cff016b5810ee018394102825ccdd8},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC, https://europepmc.org/article/PPR/PPR203930. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
The coronavirus disease 2019 (COVID-19) pandemic caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) is in urgent need of therapeutic options. High-throughput screening (HTS) offers the research field an opportunity to rapidly identify such compounds. In this work, we have developed a homogeneous cell-based HTS system using AlphaLISA detection technology for the SARS-CoV-2 nucleocapsid protein (NP). Our assay measures both recombinant NP and endogenous NP from viral lysates and tissue culture supernatants (TCS) in a sandwich-based format using two monoclonal antibodies against the NP analyte. Viral NP was detected and quantified in both tissue culture supernatants and cell lysates, with large differences observed between 24 hours and 48 hours of infection. We simulated the viral infection by spiking in recombinant NP into 384-well plates with live Vero-E6 cells and were able to detect the NP with high sensitivity and a large dynamic range. Anti-viral agents that inhibit either viral cell entry or replication will decrease the AlphaLISA NP signal. Thus, this assay can be used for high-throughput screening of small molecules and biologics in the fight against the COVID-19 pandemic. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: bioRxiv, 2020 (prima pubblicazione 2020-08-20). Identificativi: DOI 10.1101/2020.08.20.258129. Pagina: https://europepmc.org/article/PPR/PPR203930 — https://doi.org/10.1101/2020.08.20.258129. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-11-07T17:27:20.482Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.